What question did this study set out to answer?

To assess the effects of gemfibrozil on lipid profiles and hemostatic markers in hyperlipidaemic patients with stable peripheral arterial occlusive disease.

January 1, 1990Current Medical Research and Opinion

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

View Full Paper

Ask AI

Bookmark

Why the study?

Does gemfibrozil improve lipid and coagulation profiles in hyperlipidaemic patients with stable peripheral arterial occlusive disease?

Population

27 hyperlipidaemic patients with stable peripheral arterial occlusive disease

Comparison

Gemfibrozil 600 mg twice daily for 12 weeks vs 2 weeks of placebo medication

Design

Cohort

Follow-up

12 weeks

Authors

MSMark D. StringerUniversity College Dublin CSColin A. SteadmanKing's College Hospital VKVijay V. KakkarManipal Academy of Higher Education

Discussion

Member takes

Implication

Gemfibrozil-associated lipid improvements accompanied fibrinogen rise in stable PAOD; hypothesis-generating and should not yet change practice.

Key Points

To assess the effects of gemfibrozil on lipid profiles and hemostatic markers in hyperlipidaemic patients with stable peripheral arterial occlusive disease.
Conducted a self-controlled clinical study in 27 hyperlipidaemic patients with stable peripheral arterial occlusive disease (N=27).
Administered gemfibrozil at 600 mg twice daily for 12 weeks following an initial 2-week placebo run-in period.
Gemfibrozil reduced mean serum cholesterol by 11.3%, triglycerides by 42.3%, and LDL cholesterol by 19.9%, while significantly increasing HDL3 and apolipoprotein A-II.
Treatment led to significant decreases in plasma lipid peroxides and Factor VIIc alongside a mean increase of 19% in antithrombin III concentrations.
Plasma fibrinogen levels increased by a mean of 17.6%, revealing an unexpected and potentially adverse effect of therapy.

Structured PICO

Does gemfibrozil improve lipid and coagulation profiles in hyperlipidaemic patients with stable peripheral arterial occlusive disease?

Population

27 hyperlipidaemic patients with stable peripheral arterial occlusive disease

Intervention

Gemfibrozil 600 mg twice daily for 12 weeks

Comparator

2 weeks of placebo medication (patients acted as their own controls)

Outcome

Changes in serum cholesterol, triglycerides, and low density lipoprotein cholesterol levelssurrogate

Gemfibrozil effectively improves lipid profiles in patients with peripheral arterial disease but may have a potentially adverse effect by increasing plasma fibrinogen levels.

Cite This Study

Stringer et al. (1990) studied this question.

synapsesocial.com/papers/6a74c4df756843cacbb1d1bc https://doi.org/10.1185/03007999009111649

View Full Paper

Ask AI

Bookmark

Implication

Gemfibrozil-associated lipid improvements accompanied fibrinogen rise in stable PAOD; hypothesis-generating and should not yet change practice.

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider